ImmuCell

ImmuCell Corp. engages in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. Its products include first defense for scours, California mastitis test kit and purified nisin intramammary treatment for mastitis. The company was founded in 1982 and is headquartered in Portland, ME.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. Its products include first defense for scours, California mastitis test kits, and purified nisin intramammary treatment for mastitis. The company was founded in 1982 and is headquartered in Portland, ME.

PORTLAND, Maine, April 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2024, which ended March 31, 2024.

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024

ImmuCell Corporation (ICCC) Q4 2023 Earnings Call Transcript

PORTLAND, Maine, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter and year ended December 31, 2023.

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ET

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

PORTLAND, Maine, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter of 2023, which ended December 31, 2023.

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023

ImmuCell Corporation (NASDAQ:ICCC ) Q3 2023 Earnings Conference Call November 14, 2023 9:00 AM ET Company Participants Joe Diaz - Managing Partner; Lytham Partners, LLC Michael Brigham - CEO Conference Call Participants Operator Good day, everyone, and welcome to the ImmuCell Corporation's Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.

ImmuCell Corporation (ICCC) Q3 2023 Earnings Call Transcript

PORTLAND, Maine, Nov. 13, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2023.

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023

Conference Call Scheduled for Tuesday, November 14, 2023 at 9:00 AM ET Conference Call Scheduled for Tuesday, November 14, 2023 at 9:00 AM ET

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023

PORTLAND, Maine, Oct. 05, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2023, which ended September 30, 2023.

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023

PORTLAND, Maine, Aug. 29, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, announced today that it recently submitted the Chemistry, Manufacturing and Controls (CMC) Technical Section for Re-Tain ® to the FDA.

ImmuCell Announces Submission of CMC Technical Section to the FDA

ImmuCell Corporation (NASDAQ:ICCC ) Q2 2023 Earnings Conference Call August 11, 2023 9:00 AM ET Company Participants Joe Dorame - Lytham Partners, IR Michael Brigham - President and Chief Executive Officer Conference Call Participants Operator Good day, and welcome to the ImmuCell Corporation Reports Second Quarter Fiscal Year 2023 Financial Results Conference Call. All participants will be in a listen-only mode.

ImmuCell Corporation (ICCC) Q2 2023 Earnings Call Transcript

PORTLAND, Maine, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2023.

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023

PORTLAND, Maine, Aug. 07, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2023 after the market closes on Thursday, August 10, 2023. The Company has scheduled a conference call the next morning, Friday, August 11, 2023, at 9:00 AM ET to review its second quarter financial results.

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023

PORTLAND, Maine, July 11, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2023, which ended June 30, 2023.

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023

PORTLAND, Maine, June 28, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a change to its anticipated FDA submission schedule.

ImmuCell Announces Change in Timing of Anticipated FDA Submission

PORTLAND, Maine, June 21, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that Bryan K. Gathagan has been appointed to its Board of Directors.

ImmuCell Appoints Bryan K. Gathagan to Board of Directors

PORTLAND, Maine, June 15, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the approval by Gorham Savings Bank (GSB) and the Finance Authority of Maine (FAME) of the principal terms of a $3 million debt facility with the Company.

ImmuCell Announces Approval of Principal Terms of a $3 Million Debt Facility

PORTLAND, Maine, May 16, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2023 Annual Meeting of Stockholders will be conducted virtually.

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

ImmuCell Corporation (NASDAQ:ICCC ) Q1 2023 Earnings Conference Call May 12, 2023 9:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Conference Call Participants Operator Good morning, and welcome to ImmuCell Corporation Reports First Quarter 2023 Unaudited Financial Results Conference Call. All participants will be in a listen-only mode.

ImmuCell Corporation (ICCC) Q1 2023 Earnings Call Transcript

PORTLAND, Maine, May 11, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2023.

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2023

PORTLAND, Maine, May 04, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2023 after the market closes on Thursday, May 11, 2023. The Company has scheduled a conference call the next morning, Friday, May 12, 2023, at 9:00 AM ET to review its first quarter financial results.

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023

PORTLAND, Maine, April 05, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2023, which ended March 31, 2023.

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2023

ImmuCell Corporation (NASDAQ:ICCC ) Q4 2022 Earnings Conference Call February 22, 2023 9:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Conference Call Participants Operator Good morning, and welcome to ImmuCell Corporation Reports Fiscal Year 2022 Unaudited Financial Results Conference Call. All participants will be in a listen-only mode.

ImmuCell Corporation (ICCC) Q4 2022 Earnings Call Transcript

PORTLAND, Maine, Feb. 21, 2023 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the year ended December 31, 2022.

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2022

Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET

News for ImmuCell Stock (ICCC)